Shares of Mainz Biomed B.V. (MYNZ) tanked over 25% on Wednesday morning. The company announced that it priced a follow-on offering at $15 per share.
MYNZ is currently trading at $15.00, down $5.25 or 25.93%, on the Nasdaq.
Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced the pricing of its underwritten public follow-on offering of 1.5 million ordinary shares at a price of $15.00 per share for gross proceeds of $22.5 million.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.